Erschienen in:
17.08.2018 | Original Contributions
EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial
verfasst von:
Eduardo Guimarães Hourneaux de Moura, Igor Braga Ribeiro, Mariana Souza Varela Frazão, Luiz Henrique Mazzonetto Mestieri, Diogo Turiani Hourneaux de Moura, Creusa Maria Roveri Dal Bó, Vitor Ottoboni Brunaldi, Eduardo Turiani Hourneaux de Moura, Gabriel Cairo Nunes, Fábio Alberto Castillo Bustamante, Manoel dos Passos Galvão Neto, Sergio Eiji Matuguma, Wanderley Marques Bernardo, Marco Aurélio Santo
Erschienen in:
Obesity Surgery
|
Ausgabe 1/2019
Einloggen, um Zugang zu erhalten
Abstract
Background
Obesity is a disease that is highly prevalent in Brazil, and the associated comorbidities represent a major global public health challenge. Botulinum toxin type A (BTX-A) is a potent neurotoxin and inhibitor of gastric smooth muscle activity. In theory, BTX-A administration should promote early satiety and weight loss because it delays gastric emptying by inhibiting acetylcholine-mediated peristalsis, which is primarily responsible for gastric motility. Because results in the literature are discrepant, the efficacy of intragastric injections of BTX-A as a primary treatment for obesity remains unknown. The objective of this prospective, double-blind, single-center randomized study was to evaluate the effects of endoscopic ultrasound-guided intragastric BTX-A injections, as a bridge to bariatric surgery, in super-obese patients.
Methods
Thirty-two super-obese patients were randomized to one of two groups: BTX-A, in which 200 units of BTX-A were injected into the gastric antrum and body; and control, in which the same injections were performed with 0.9% saline. Weight, body mass index (BMI), and loss of excess weight were measured monthly over a 6-month period. Gastric emptying scintigraphy was performed before and after the procedure.
Results
The patients in both groups showed significant weight loss over the course of the study (p < 0.001). There were no statistically significant differences between the groups regarding weight loss, excess weight, total loss of excess weight, total weight loss, or change in BMI.
Conclusions
Intragastric injection of BTX-A does not appear to be an effective method of achieving preoperative weight loss in super-obese patients.